Nu Skin Enterprises (NYSE:NUS) Releases FY20 Earnings Guidance
Nu Skin Enterprises (NYSE:NUS) updated its FY20 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $2.00-2.40 for the period, compared to the Thomson Reuters consensus estimate of $3.31. The company issued revenue guidance of $2.17-2.30 billion, compared to the consensus revenue estimate of $2.47 billion.Nu Skin Enterprises also updated its FY 2020
After-Hours guidance to 2.00-2.40 EPS.
Nu Skin Enterprises stock traded up $1.75 during midday trading on Friday, reaching $31.72. The company had a trading volume of 191,776 shares, compared to its average volume of 613,827. The company has a market capitalization of $1.96 billion, a P/E ratio of 15.32, a P/E/G ratio of 1.14 and a beta of 0.78. Nu Skin Enterprises has a 12-month low of $29.09 and a 12-month high of $67.00. The firm’s fifty day simple moving average is $38.18 and its 200-day simple moving average is $40.32. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.24.
Nu Skin Enterprises (NYSE:NUS) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.72 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.72. Nu Skin Enterprises had a return on equity of 23.52% and a net margin of 4.59%. The company had revenue of $583.36 million during the quarter, compared to analyst estimates of $582.49 million. During the same period in the previous year, the business earned $1.05 EPS. Nu Skin Enterprises’s quarterly revenue was down 14.6% on a year-over-year basis. On average, analysts expect that Nu Skin Enterprises will post 3.11 EPS for the current fiscal year.
NUS has been the subject of several recent research reports. Zacks Investment Research downgraded Nu Skin Enterprises from a hold rating to a sell rating and set a $44.00 price objective for the company. in a research note on Monday, November 11th. Citigroup lowered their target price on shares of Nu Skin Enterprises from $43.00 to $33.00 and set a neutral rating on the stock in a research note on Friday. Stifel Nicolaus raised shares of Nu Skin Enterprises from a sell rating to a hold rating and upped their target price for the stock from $38.50 to $45.00 in a report on Tuesday, October 29th. DA Davidson reiterated an in-line rating and issued a $35.00 target price on shares of Nu Skin Enterprises in a research report on Thursday. They noted that the move was a valuation call. Finally, Bank of America decreased their price target on shares of Nu Skin Enterprises from $40.00 to $30.00 and set an underperform rating on the stock in a research note on Thursday. Two analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $44.63.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products.
See Also: What is a back-end load?
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.